Adial Pharmaceuticals Temettü
Temettü kriter kontrolleri 0/6
Adial Pharmaceuticals does not have a record of paying a dividend.
Anahtar bilgiler
n/a
Temettü verimi
-67.6%
Geri Alım Getirisi
Toplam Hissedar Getirisi | -67.6% |
Gelecekteki Temettü Verimi | n/a |
Temettü Büyümesi | n/a |
Bir sonraki temettü ödeme tarihi | n/a |
Eski temettü tarihi | n/a |
Hisse başına temettü | n/a |
Ödeme oranı | n/a |
Son temettü güncellemeleri
Güncelleme yok
Recent updates
Adial Clinical Trial: A Fluff Or A Win?
Aug 22Adial Pharmaceuticals GAAP EPS of -$0.16 beats by $0.01
Aug 16Revisiting Adial Pharmaceuticals: EMA Approval For Alcohol Use Disorder Pill Is A Critical Catalyst
Jun 21Adial Pharmaceuticals shares +5% on receiving third patent for opioid use disorder candidate
Jan 11Adial Pharmaceuticals inks stock purchase agreement with Keystone Capital
Nov 25Ödemelerde İstikrar ve Büyüme
Temettü verilerini getirme
İstikrarlı Temettü: Insufficient data to determine if ADIL's dividends per share have been stable in the past.
Büyüyen Temettü: Insufficient data to determine if ADIL's dividend payments have been increasing.
Piyasaya Karşı Temettü Getirisi
Adial Pharmaceuticals Piyasaya Karşı Temettü Getirisi |
---|
Segment | Temettü Verimi |
---|---|
Şirket (ADIL) | n/a |
Pazarın Alt %25'i (US) | 1.5% |
Pazarın En İyi %25'i (US) | 4.5% |
Sektör Ortalaması (Pharmaceuticals) | 2.3% |
Analist tahmini (ADIL) (3 yıla kadar) | n/a |
Önemli Temettü: Unable to evaluate ADIL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
Yüksek Temettü: Unable to evaluate ADIL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Hissedarlara Ödenen Kazanç
Kazanç Kapsamı: Insufficient data to calculate ADIL's payout ratio to determine if its dividend payments are covered by earnings.
Hissedarlara Nakit Ödeme
Nakit Akışı Kapsamı: Unable to calculate sustainability of dividends as ADIL has not reported any payouts.